See more : PT Natura City Developments Tbk (CITY.JK) Income Statement Analysis – Financial Results
Complete financial analysis of SITE Centers Corp. (SITC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of SITE Centers Corp., a leading company in the REIT – Retail industry within the Real Estate sector.
You may be interested
- Paladin Energy Ltd (PALAF) Income Statement Analysis – Financial Results
- Jaipan Industries Limited (JAIPAN.BO) Income Statement Analysis – Financial Results
- Cohu, Inc. (COHU) Income Statement Analysis – Financial Results
- Shenzhen Jasic Technology Co.,Ltd. (300193.SZ) Income Statement Analysis – Financial Results
- Meier Tobler Group AG (0QQK.L) Income Statement Analysis – Financial Results
SITE Centers Corp. (SITC)
About SITE Centers Corp.
SITE Centers is an owner and manager of open-air shopping centers that provide a highly-compelling shopping experience and merchandise mix for retail partners and consumers. The Company is a self-administered and self-managed REIT operating as a fully integrated real estate company, and is publicly traded on the New York Stock Exchange under the ticker symbol SITC.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 546.28M | 540.81M | 492.34M | 416.76M | 447.75M | 654.86M | 879.45M | 969.51M | 995.10M | 953.77M | 888.79M | 800.38M | 771.02M | 803.07M | 819.31M | 931.47M | 944.85M | 818.10M | 727.18M | 598.93M | 476.10M | 357.24M | 322.24M | 285.79M | 263.93M | 228.17M | 169.04M | 130.91M | 108.60M | 81.80M | 51.70M |
| Cost of Revenue | 165.72M | 169.98M | 152.79M | 138.40M | 139.66M | 207.99M | 250.92M | 277.08M | 293.69M | 281.11M | 255.35M | 233.08M | 235.80M | 246.16M | 254.47M | 257.12M | 133.33M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 380.55M | 370.82M | 339.56M | 278.36M | 308.09M | 446.87M | 628.53M | 692.42M | 701.41M | 672.66M | 633.44M | 567.30M | 535.22M | 556.91M | 564.84M | 674.35M | 811.52M | 818.10M | 727.18M | 598.93M | 476.10M | 357.24M | 322.24M | 285.79M | 263.93M | 228.17M | 169.04M | 130.91M | 108.60M | 81.80M | 51.70M |
| Gross Profit Ratio | 69.66% | 68.57% | 68.97% | 66.79% | 68.81% | 68.24% | 71.47% | 71.42% | 70.49% | 70.53% | 71.27% | 70.88% | 69.42% | 69.35% | 68.94% | 72.40% | 85.89% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 50.87M | 46.56M | 55.05M | 52.88M | 58.38M | 61.64M | 89.85M | 76.10M | 73.38M | 84.48M | 79.56M | 76.44M | 85.22M | 85.57M | 94.37M | 97.72M | 81.24M | 60.68M | 54.05M | 47.13M | 40.82M | 29.39M | 24.38M | 20.45M | 17.77M | 12.92M | 11.06M | 8.44M | 6.40M | 5.60M | 4.10M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -15.36M | -15.84M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 50.87M | 46.56M | 55.05M | 52.88M | 58.38M | 61.64M | 89.85M | 76.10M | 73.38M | 84.48M | 79.56M | 76.44M | 85.22M | 85.57M | 79.00M | 81.88M | 81.24M | 60.68M | 54.05M | 47.13M | 40.82M | 29.39M | 24.38M | 20.45M | 17.77M | 12.92M | 11.06M | 8.44M | 6.40M | 5.60M | 4.10M |
| Other Expenses | 0.00 | 203.55M | 185.77M | 170.67M | 165.09M | 242.10M | -95.36M | 39.62M | 31.23M | 19.65M | -6.63M | -17.88M | 222.66M | 222.86M | 227.19M | 242.03M | 328.08M | 401.31M | 349.01M | 281.19M | 436.63M | 326.34M | 302.62M | 114.62M | 104.34M | 204.15M | 139.39M | 111.53M | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 45.87M | 250.11M | 240.82M | 223.55M | 223.47M | 303.74M | 446.85M | 465.62M | 475.43M | 487.31M | 397.63M | 325.23M | 307.88M | 308.44M | 321.55M | 596.87M | 409.32M | 461.99M | 403.06M | 328.32M | 477.45M | 355.73M | 326.99M | 135.07M | 122.11M | 217.07M | 150.45M | 119.96M | -43.60M | -33.40M | -23.10M |
| Cost & Expenses | 430.47M | 420.09M | 393.61M | 361.95M | 363.13M | 511.73M | 697.77M | 742.70M | 769.12M | 768.42M | 652.99M | 558.30M | 543.67M | 554.60M | 576.02M | 596.87M | 542.66M | 461.99M | 403.06M | 328.32M | 477.45M | 355.73M | 326.99M | 135.07M | 122.11M | 217.07M | 150.45M | 119.96M | -43.60M | -33.40M | -23.10M |
| Interest Income | 0.00 | 0.00 | 0.00 | 11.89M | 18.01M | 20.44M | 28.36M | 37.05M | 29.21M | 15.93M | 23.54M | 15.80M | 9.83M | 7.35M | 12.11M | 5.47M | 8.81M | 0.00 | 0.00 | 0.00 | 5.08M | 5.91M | 6.42M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 82.00M | 77.69M | 77.03M | 77.60M | 84.72M | 141.31M | 188.65M | 217.59M | 241.73M | 237.12M | 228.87M | 221.42M | 229.72M | 226.46M | 237.94M | 244.21M | 258.15M | 0.00 | 0.00 | 0.00 | 240.26M | 101.97M | 92.37M | 100.83M | 87.40M | 77.92M | 67.52M | 49.54M | 25.50M | 21.20M | 8.60M |
| Depreciation & Amortization | 212.46M | 203.55M | 185.77M | 170.67M | 165.09M | 242.10M | 346.20M | 389.52M | 402.05M | 402.83M | 318.08M | 248.78M | 222.66M | 222.86M | 227.19M | 242.03M | 224.38M | 193.53M | 170.70M | 132.65M | 95.22M | 78.37M | 64.49M | 54.20M | 52.44M | 43.18M | 32.31M | 25.06M | 23.60M | 17.40M | 10.90M |
| EBITDA | 339.27M | 361.16M | 372.32M | 263.06M | 323.04M | 338.23M | 577.39M | 667.87M | 656.21M | 634.70M | 514.62M | 456.09M | 230.11M | 252.22M | 244.64M | 337.90M | 629.59M | 549.64M | 494.82M | 403.26M | 417.48M | 222.98M | 64.49M | 196.19M | 415.86M | 359.46M | 285.80M | 218.10M | 175.80M | 132.60M | 85.70M |
| EBITDA Ratio | 62.11% | 66.78% | 75.62% | 63.12% | 72.15% | 51.65% | 53.41% | 73.10% | 68.87% | 66.55% | 64.99% | 65.47% | 61.42% | 60.30% | 60.63% | 52.91% | 66.63% | 67.24% | 68.39% | 67.63% | 19.72% | 22.36% | 18.54% | 71.70% | 73.60% | 23.68% | 28.03% | 27.51% | 161.60% | 162.10% | 165.76% |
| Operating Income | 339.27M | 157.61M | 186.55M | 92.39M | 157.95M | 96.12M | 637.03M | 692.42M | 701.41M | 672.66M | 221.41M | 196.76M | 214.91M | 65.10M | -119.34M | 169.00M | 261.41M | 250.78M | 282.99M | 271.23M | 240.26M | 101.97M | 92.37M | 100.83M | 87.40M | 77.92M | 67.52M | 49.54M | 25.50M | 21.20M | 8.60M |
| Operating Income Ratio | 62.11% | 29.14% | 37.89% | 22.17% | 35.28% | 14.68% | 72.44% | 71.42% | 70.49% | 70.53% | 24.91% | 24.58% | 27.87% | 8.11% | -14.57% | 18.14% | 27.67% | 30.65% | 38.92% | 45.29% | 50.46% | 28.54% | 28.67% | 35.28% | 33.11% | 34.15% | 39.94% | 37.85% | 23.48% | 25.92% | 16.63% |
| Total Other Income/Expenses | -71.50M | -188.46M | -12.29M | -62.36M | -41.49M | -76.27M | -456.83M | -273.51M | -490.55M | -194.30M | -510.01M | -113.39M | -250.28M | -211.28M | -198.46M | -279.60M | -71.96M | -182.52M | -139.86M | -86.31M | 73.04M | -38.81M | -74.95M | -67.88M | 0.00 | -314.76M | -252.10M | 0.00 | -152.20M | 0.00 | 0.00 |
| Income Before Tax | 267.77M | 169.61M | 126.97M | 37.72M | 102.48M | -108.44M | -402.67M | -10.41M | -231.60M | 22.96M | 4.60M | -13.62M | -41.54M | -146.18M | -317.80M | -89.94M | 189.90M | 173.59M | 184.26M | 184.31M | 240.26M | 101.97M | 92.37M | 100.83M | 87.40M | 77.92M | 67.52M | 49.54M | 25.50M | 21.20M | 8.60M |
| Income Before Tax Ratio | 49.02% | 31.36% | 25.79% | 9.05% | 22.89% | -16.56% | -45.79% | -1.07% | -23.27% | 2.41% | 0.52% | -1.70% | -5.39% | -18.20% | -38.79% | -9.66% | 20.10% | 21.22% | 25.34% | 30.77% | 50.46% | 28.54% | 28.67% | 35.28% | 33.11% | 34.15% | 39.94% | 37.85% | 23.48% | 25.92% | 16.63% |
| Income Tax Expense | 2.05M | 816.00K | 1.55M | 1.13M | 659.00K | 862.00K | 1.62M | 1.78M | 6.29M | 1.86M | 2.71M | 1.16M | 1.04M | 47.99M | -691.00K | -17.43M | -14.64M | -2.48M | 342.00K | 1.47M | -240.26M | -101.97M | -92.37M | -100.83M | -87.40M | -77.92M | -67.52M | -49.54M | -25.50M | -21.20M | -8.60M |
| Net Income | 265.70M | 168.72M | 124.94M | 35.72M | 100.70M | -109.30M | -241.69M | 60.01M | -72.17M | 117.28M | -10.18M | -25.82M | -15.85M | -209.36M | -356.59M | -57.78M | 276.05M | 253.26M | 282.64M | 269.76M | 240.26M | 101.97M | 92.37M | 100.83M | 87.40M | 77.92M | 67.52M | 49.54M | 25.50M | 21.20M | 8.60M |
| Net Income Ratio | 48.64% | 31.20% | 25.38% | 8.57% | 22.49% | -16.69% | -27.48% | 6.19% | -7.25% | 12.30% | -1.14% | -3.23% | -2.06% | -26.07% | -43.52% | -6.20% | 29.22% | 30.96% | 38.87% | 45.04% | 50.46% | 28.54% | 28.67% | 35.28% | 33.11% | 34.15% | 39.94% | 37.85% | 23.48% | 25.92% | 16.63% |
| EPS | 4.85 | 2.96 | 2.04 | 0.74 | 2.20 | -2.37 | -5.26 | 1.31 | -1.60 | 2.00 | -0.25 | -0.72 | -0.47 | -6.84 | -17.96 | -3.48 | 13.41 | 13.12 | 15.14 | 16.37 | 16.66 | 11.55 | 12.07 | 12.95 | 10.27 | 9.89 | 7.43 | 6.06 | 4.61 | 4.83 | 2.74 |
| EPS Diluted | 4.85 | 2.92 | 2.04 | 0.74 | 2.20 | -2.37 | -5.26 | 1.31 | -1.60 | 2.00 | -0.25 | -0.72 | -0.47 | -6.84 | -17.96 | -3.47 | 13.34 | 13.05 | 15.00 | 16.15 | 16.37 | 11.34 | 11.97 | 12.95 | 9.96 | 9.50 | 7.43 | 5.99 | 4.61 | 4.76 | 2.74 |
| Weighted Avg Shares Out | 52.36M | 53.25M | 52.00M | 48.33M | 45.76M | 46.13M | 45.92M | 45.66M | 45.11M | 44.76M | 40.80M | 35.88M | 33.78M | 30.59M | 19.85M | 16.62M | 16.76M | 15.09M | 15.02M | 13.38M | 11.35M | 8.83M | 7.65M | 7.79M | 8.51M | 7.88M | 7.18M | 7.66M | 5.53M | 4.39M | 3.14M |
| Weighted Avg Shares Out (Dil) | 52.41M | 53.47M | 52.29M | 48.44M | 45.81M | 46.13M | 45.92M | 45.70M | 45.11M | 44.76M | 40.80M | 35.88M | 33.93M | 30.59M | 19.85M | 16.64M | 16.85M | 15.18M | 15.17M | 13.56M | 11.55M | 8.99M | 7.72M | 7.79M | 8.78M | 8.20M | 7.18M | 7.66M | 5.53M | 4.45M | 3.14M |
Context Therapeutics Announces Poster Presentation at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting
PHILADELPHIA, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing T cell engagers for solid tumors, today announced a poster regarding the Company's clinical asset, CTIM-76, a Claudin 6 x CD3...
Adagene Announces Upcoming Poster Presentations on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
SAN DIEGO and SUZHOU, China, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced poster presentations at the upcoming SITC 39th Annual Meeting, taking place...
Mural Oncology to Present Clinical and Preclinical Data at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
WALTHAM, Mass and DUBLIN, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, today...
Beyond Cancer to Present Preclinical Data of Ultra-High Concentration Nitric Oxide (UNO) Low Volume Therapy at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting
HAMILTON, Bermuda, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., a clinical stage biotechnology company developing ultra-high concentration nitric oxide (UNO) as an immunotherapeutic for solid tumors, today announced being selected to present two poster presentations at the upcoming...
MiNK Therapeutics to Present Data From iNKT Cell Programs at SITC 2024
NEW YORK, Oct. 04, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases,...
Medicenna to Present Clinical and Preclinical Data at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
Updated clinical results to be presented from the ongoing Phase 1/2 ABILITY-1 study of MDNA11 in advanced or metastatic solid tumors
Xilio Therapeutics Announces Upcoming Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
WALTHAM, Mass., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced an upcoming poster presentation at the Society for Immunotherapy of...
Carisma Therapeutics Announces Upcoming Presentations at SITC 2024
PHILADELPHIA , Oct. 4, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced its upcoming poster presentations at the Society for Immunotherapy of Cancer (SITC),...
Kineta Announces KVA12123 Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024
SEATTLE, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (OTC Pink: KANT) , a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that its abstract on the KVA12123 clinical...
Candel Therapeutics to Present Preclinical Data on Therapeutic Potential of CAN-3110 in Melanoma at SITC 2024 Annual Meeting
NEEDHAM, Mass., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the Company will present a poster...
Source: https://incomestatements.info
Category: Stock Reports